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for the WHO Multi-Country Survey on Maternal and Newborn Health Research Network
Summary
Background Despite the global burden of morbidity and mortality associated with preterm birth, little evidence is 
available for use of antenatal corticosteroids and tocolytic drugs in preterm births in low-income and middle-income 
countries. We analysed data from the WHO Multicountry Survey on Maternal and Newborn Health (WHOMCS) to 
assess coverage for these interventions in preterm deliveries.
Methods WHOMCS is a facility-based, cross-sectional survey database of birth outcomes in 359 facilities in 
29 countries, with data collected prospectively from May 1, 2010, to Dec 31, 2011. For this analysis, we included 
deliveries after 22 weeks’ gestation and we excluded births that occurred outside a facility or quicker than 3 h after 
arrival. We calculated use of antenatal corticosteroids in women who gave birth between 26 and 34 weeks’ gestation, 
when antenatal corticosteroids are known to be most benefi cial. We also calculated use in women at 22–25 weeks’ 
and 34–36 weeks’ gestation. We assessed tocolytic drug use, with and without antenatal corticosteroids, in 
spontaneous, uncomplicated preterm deliveries at 26–34 weeks’ gestation.
Findings Of 303 842 recorded deliveries after 22 weeks’ gestation, 17 705 (6%) were preterm. 3900 (52%) of 7547 women 
who gave birth at 26–34 weeks’ gestation, 94 (19%) of 497 women who gave birth at 22–25 weeks’ gestation, and 
2276 (24%) of 9661 women who gave birth at 35–36 weeks’ gestation received antenatal corticosteroids. Rates of 
antenatal corticosteroid use varied between countries (median 54%, range 16–91%; IQR 30–68%). Of 4677 women 
who were potentially eligible for tocolysis drugs, 1276 (27%) were treated with bed rest or hydration and 2248 (48%) 
received no treatment. β-agonists alone (n=346, 7%) were the most frequently used tocolytic drug. Only 848 (18%) of 
potentially eligible women received both a tocolytic drug and antenatal corticosteroids.
Interpretation Use of interventions was generally poor, despite evidence for their benefi t for newborn babies. 
A substantial proportion of antenatal corticosteroid use occurred at gestational ages at which benefi t is controversial, 
and use of less eff ective or potentially harmful tocolytic drugs was common. Implementation research and contextualised 
health policies are needed to improve drug availability and increase compliance with best obstetric practice.
Funding UNDP–UNFPA–UNICEF–WHO–World Bank Special Programme of Research, Development and Research 
Training in Human Reproduction (HRP); WHO; USAID; Ministry of Health, Labour and Welfare of Japan; Gynuity 
Health Projects.
Copyright © 2014. World Health Organization. Published by Elsevier Ltd/Inc/BV. All rights reserved. 
Introduction
More than 15 million infants are born preterm every 
year and preterm birth is the largest cause of death 
among newborn babies (age up to 28 days) and the 
second largest cause of death in children younger than 
5 years.1 More than 60% of preterm deliveries occur in 
Africa and Asia. The deleterious eff ects of preterm 
delivery on newborn babies can be mitigated through 
appropriate use of proven interventions such as 
antenatal corticosteroids for fetal lung maturation 
(along with other benefi ts)2 and tocolytic drugs to delay 
delivery and potentiate the eff ects of antenatal 
corticosteroids or allow transfer to a higher-level facility 
before delivery.3
Injections of corticosteroids before delivery to induce 
fetal lung maturation and thereby prevent newborn 
morbidity and mortality has been comprehensively 
studied for nearly four decades.4 The most recent 
Cochrane review (2006) for use of antenatal corticosteroids 
in women with preterm delivery included 21 randomised 
controlled trials of 3885 women and 4269 babies.2 
Investigators concluded that antenatal corticosteroid use 
was associated with an overall 31% reduction in neonatal 
deaths, and signifi cant reductions in risks of respiratory 
distress syndrome (34%), cerebroventricular haemorrhage 
(46%), necrotising enterocolitis (54%), need for 
respiratory support or intensive-care admission (20%), 
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Antenatal corticosteroids were eff ective when given from 
26 weeks’ to 34 weeks’ plus 6 days gestation (even if given 
less than 24 h before delivery) and did not increase risk of 
maternal death, chorioamnionitis, or puerperal sepsis. A 
meta-analysis of the four randomised controlled trials for 
antenatal corticosteroids for preterm births in middle-
income countries suggested that the reduction in 
mortality might be greater in these countries than in 
high-income countries.5 Benefi t of antenatal 
corticosteroids outside this gestational age range is 
controversial; however, observational evidence suggests 
eff ectiveness when given between 22 weeks’ and 26 weeks’ 
gestation,6 and investigators of one trial reported that 
antenatal betamethasone given to women pregnant with 
term infants reduced neonatal respiratory distress and 
admission to neonatal special-care units in newborn 
babies born by elective caesarean section.7 Despite the 
global burden of newborn morbidity and mortality related 
to preterm births, uptake of antenatal corticosteroids 
worldwide has been poor—the Bellagio Child Survival 
Study group8 estimated antenatal corticosteroid coverage 
in 2000 to be just 5% for the 42 countries that had 90% of 
the world’s under-5 deaths. Recent data for worldwide use 
of antenatal corticosteroids are not available.
Spontaneous preterm labour causes 40–45% of preterm 
births.9 Tocolytic drugs (such as β-agonists, calcium-
channel blockers, and oxytocin antagonists) can be used 
as temporising measures to inhibit labour progression 
for up to 7 days.10–12 Use of tocolytic drugs alone has not 
been shown to reduce perinatal mortality (although trials 
have been underpowered for this outcome).3 However, 
use of the drugs to delay delivery is recommended to 
permit transfer to a higher-level facility and to potentiate 
the eff ects of corticosteroids (and hence should be used 
in conjunction with antenatal corticosteroids).11,12 We did 
not fi nd any published reports on patterns of tocolytic 
drug use in preterm labour in low-income and middle-
income countries, despite its importance in the 
management of preterm birth.
We did an analysis of the WHO Multicountry Survey of 
Maternal and Newborn Health (WHOMCS) dataset for 
more than 314 000 facility-based deliveries in 29 countries. 
We aimed to describe patterns of use of antenatal 
corticosteroids in preterm deliveries and assess the use of 
tocolytic drugs in spontaneous preterm deliveries.
Methods
Study design and participants
WHOMCS was a cross-sectional, facility-based survey of 
deliveries between May 1, 2010, and Dec 31, 2011. 
WHOMCS aimed to characterise severe maternal, 
perinatal, and neonatal morbidity for a worldwide network 
of health facilities, with particular focus on WHO 
maternal near-miss indicators.13 Methodological details 
for WHOMCS have been described elsewhere.13,14 
Investi gators used a stratifi ed, multistage cluster sampling 
approach to obtain a global sample of countries from 
Africa, Asia, Latin America, and the Middle East. Within 
each country, the capital city was sampled, along with 
two randomly selected provinces (probability proportional 
to population). From these areas, seven facilities that had 
more than 1000 deliveries per year and the capacity to do 
caesarean sections were randomly selected (if fewer than 
seven facilities were available, then all were selected). All 
facilities that were chosen agreed to participate. Data were 
collected for 2 months in institutions with 6000 or more 
deliveries every year and for 3 months in institutions with 
fewer than 6000 deliveries every year. When facilities 
expected fewer than 3000 deliveries, the data collection 
period was extended to 4 months.
Study participants were all women who gave birth in 
participating facilities and women with a severe maternal 
outcome (death or near-miss) associated with pregnancy, 
childbirth, or puerperium. Data were obtained 
prospectively, from time of presentation at the facility 
until discharge or 7 days post partum (whichever was 
fi rst). Maternal or perinatal adverse outcomes that 
occurred after discharge or day 7 or during a post-partum 
referral were not included. Data collectors reviewed 
medical records and abstracted de-identifi ed data from 
records into the individual data form at the time of 
discharge, transfer, or death. An institutional data form 
about available obstetric and newborn services was 
completed in consultation with the head of the department 
of obstetrics for each facility. Overall, 359 facilities in 
29 countries participated in WHOMCS, and data from 
314 623 women were recorded. For the purposes of 
comparison, we defi ned high-income countries (Japan 
and Qatar) and low-income and middle-income countries 
(the remaining 27 countries) according to the World 
Bank’s classifi cation for income group’s WHOMCS was 
approved by the WHO Ethics Review Committee and 
relevant ethics clearance bodies in participating countries. 
All authors had access to the WHO Multicountry Survey 
database; JPV, JPS, and AMG were responsible for the 
decision to submit the manuscript for publication.
Procedures
WHOMCS captured information about a range of 
maternal sociodemographic, medical, and obstetric 
characteristics and outcomes for mothers and newborn 
babies. The gestational age was recorded in completed 
weeks on the basis of best available obstetric estimate; the 
method of estimation was not recorded. Preterm births 
were defi ned as infants born before 37 weeks of gestation. 
The use of antenatal corticosteroids in preterm births was 
recorded; however, the type, timing, number of doses, and 
dosing schedule was not. The use of fi ve drug classes as 
tocolytic drugs for preterm labour was also 
recorded—β-agonists (eg, terbutaline, ritodrine), non-
steroidal anti-infl ammatory drugs (NSAIDs) and cyclo-
oxygenase (COX) inhibitors (eg, indometacin), 
calcium-channel blockers (eg, nifedipine), oxytocin 
antagonists (eg, atosiban), and magnesium sulphate. Use 
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of bed rest, hydration, or no treatment for preterm labour 
was also recorded.
Statistical analysis
For our analysis, we included pregnancies at or longer 
than 22 weeks’ gestation and excluded abortions, ectopic 
pregnancies, and pregnancies with unknown gestational 
age. We excluded deliveries that occurred before a 
woman’s arrival at the facility or within 3 h of arrival 
because antenatal corticosteroids and tocolytic drugs 
would be less applicable in these contexts. Preterm 
deliveries were stratifi ed into three mutually exclusive 
groups: 22–25 weeks’, 26–34 weeks’, and 35–36 weeks’ 
gestation. We established the rate of documented 
antenatal corticosteroid use, both overall and for each 
country. We identifi ed women who had spontaneous 
preterm labour at 26–34 weeks’ gestation and who did 
not have a major contraindication to tocolysis (ie, 
eclampsia, placental abruption, or sepsis). We reported 
on the documented use of tocolysis treatments, with and 
without antenatal corticosteroids, in these women. We 
analysed the crude and adjusted associated eff ect of 
maternal, neonatal, and facility characteristics on 
administration of antenatal corticosteroids by using a 
multilevel logistic regression model. We also reported 
their individual eff ects with odds ratios, and adjusted 
odds ratios and their 95% CIs. Maternal characteristics 
recorded were age, marital status, education level, parity, 
mode of delivery, presence of disorders (ie, chronic 
hypertension, pre-eclampsia or eclampsia, pyelonephritis, 
infl uenza-like illness, other infections or sepsis, 
HIV/AIDS, and malaria and dengue fever), and number 
Births at 22–25 weeks’ gestation 
(n=497)
Births at 26–34 weeks’ gestation 
(n=7547)
Births at 35–36 weeks’ gestation 
(n=9661)



















Did not receive antenatal corticosteroids 362 (73%) 235 (71%) 112 (77%) 3373 (45%) 2190 (45%) 1163 (45%) 6934 (72%) 5029 (74%) 1894 (67%)
Received antenatal corticosteroids 94 (19%) 69 (21%) 25 (17%) 3900 (52%) 2522 (51%) 1374 (53%) 2276 (24%) 1440 (21%) 827 (29%)
Use of antenatal corticosteroids not recorded 41 (8%) 25 (8%) 9 (6%) 274 (4%) 194 (4%) 75 (3%) 451 (5%) 349 (5%) 99 (4%)
Columns might not add to 100% because of rounding error. *Does not include 22 women with missing labour status. †Women who delivered preterm after spontaneous onset of labour. ‡Women who delivered 
preterm after induction of labour or pre-labour delivery (ie, caesarean section). §Does not include 29 women with missing labour status. ¶Does not include 23 women with missing labour status. 
Table 1: Use of antenatal corticosteroids in preterm births (n=17 705 deliveries)
Figure 1: Population profi le
*Complicated spontaneous preterm birth includes women who have eclampsia, placental abruption, or sepsis (ie, use of tocolytic drugs is contraindicated). 
314 623 women
303  842 women
10 781 women excluded
568 non-deliveries (ie, ectopic pregnancies, 
abortions)
3898 gestation age unknown or younger than 
22 weeks’ 
6315 deliveries before arrival or within 3 h of arrival
286 137 women
 Term deliveries (37 weeks’ gestation or later)
497 women
 22–25 weeks’ gestation
4677 women
 Uncomplicated spontaneous 
 preterm birth
229 women
 Complicated spontaneous 
 preterm birth*
7547 women
 26–34 weeks’ gestation
9661 women
 35–36 weeks’ gestation
29 women
 Missing labour status, preterm birth
4906 women
 Spontaneous preterm birth
2612 women
 Provider-initiated preterm birth 
 (induced or caesarean section)
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and sex of fetuses. Facility characteristics recorded were 
location, level of facility, and level of services available.
We used SPSS version 20.0.0 procedure MULTIPLE 
IMPUTATION to impute missing values for all model 
variables (see missing rates in table 1). Overall missing 
rates were 5% or less for all variables, except for years of 
education (7·7%). Five imputed datasets were created and 
used in our model. We converted continuous variables 
(maternal age, years of education, and parity) to categorical 
variables after imputation for modelling. We also adjusted 
our model (using SPSS function GENLINMIXED) for 
clustering due to hierarchical design of the survey 
(clustering of women within facilities and facilities within 
countries was accounted for by use of health facilities as 
sampling units and countries as strata) with random 
intercepts at the country and facility level. Because of the 
weighted sampling design of the WHOMCS, our analysis 
was self-weighted and no further weighting was applied.
Role of the funding source
JPV, JPS, AMG, MB, and MT are employed by WHO. 
Some of the funds for the study were from WHO. The 
non-WHO sponsors of the study had no role in study 
design, data collection, data analysis, data interpretation, 
or writing of the report. All authors had access to the 
WHOMCS database. JPV, JPS, and AMG made the 
decision to submit for publication.
Results
Of 303 842 women included in our analysis, 17 705 (6%) 
gave birth preterm (fi gure 1). These deliveries occurred 
across 359 facilities, mainly in secondary (N=94 740, 31%) 
Coverage of corticosteroids in all deliveries at 
26–34 weeks’ gestation
Coverage of both tocolytic drugs and antenatal 
corticosteroids in uncomplicated, spontaneous 
deliveries at 26–34 weeks’ gestation
Women who 
received drugs (n)
Proportion (%) 95% CI* Women who 
received drugs (n)
Proportion (%) 95% CI*
Afghanistan 48 (297) 16% 6·6–34·5 2 (207) 1% 0·2–5·2
Angola 33 (129) 26% 12·2–46·0 2 (79) 3% 0·8–7·6
Argentina 136 (185) 74% 62·9–82·0 52 (88) 59% 46·7–70·5
Brazil 86 (288) 30% 13·9–52·9 14 (105) 13% 8·6–20·1
Cambodia 73 (127) 58% 47·2–67·1 9 (75) 12% 3·7–32·8
China 158 (234) 68% 58·7–75·2 52 (125) 42% 30·0 - 54·2
Democratic Republic of the Congo 26 (159) 16% 6·8–34·4 9 (131) 7% 1·7–23·6
Ecuador 84 (237) 35% 16·8–59·8 34 (148) 23% 9·7–45·3
India 1021 (1481) 69% 60·8–76·1 140 (1102) 13% 7·5–20·7
Japan 30 (52) 58% 38·2–75·0 12 (22) 55% 28·8–78·1
Jordan 19 (21) 91% 78·0–100 5 (8) 63% 29·0–96·1
Kenya 173 (542) 32% 21·3–44·8 23 (334) 7% 3·0–15·0
Lebanon 43 (76) 57% 41·4–70·6 16 (46) 35% 19·9–53·4
Mexico 300 (558) 54% 38·9–68·0 91 (391) 23% 18·9–28·3
Mongolia 108 (156) 69% 62·8–75·0 17 (55) 31% 23·0–40·1
Nepal 46 (236) 20% 5·7–49·1 0 (187) 0 ··
Nicaragua 130 (184) 71% 63·8–76·7 56 (92) 61% 45·0–74·7
Niger 12 (60) 20% 7·5–43·7 2 (42) 5% 1·2–17·4
Nigeria 109 (367) 30% 19·7–42·1 27 (188) 14% 5·9–31·1
Occupied Palestinian territory 22 (25) 88% 75·3–100 4 (4) 100% ··
Pakistan 250 (398) 63% 53·3–71·4 37 (195) 19% 9·6–34·0
Paraguay 68 (99) 69% 60·3–76·0 28 (56) 50% 43·4–56·6
Peru 302 (403) 75% 67·1–81·4 78 (183) 43% 30·9–55·2
Philippines 120 (256) 47% 37·0–57·0 33 (193) 17% 10·5–26·6
Qatar 9 (29) 31% 14·2–47·8 1 (18) 6% 0–16·2
Sri Lanka 287 (439) 65% 56·5–73·3 47 (220) 21% 12·9–33·3
Thailand 108 (244) 44% 34·6–54·3 44 (172) 26% 18·8–33·8
Uganda 41 (154) 27% 19·3–35·5 0 (110) 0% ··
Vietnam 58 (111) 52% 40·6–63·6 13 (101) 13% 5·1–29·1
Total 3900 (7547) 52% 47·5–55·8 848 (4677) 18·1% 15·4–21·2
*95% CIs are adjusted for hierarchical survey design.
Table 2: Coverage of antenatal corticosteroids and tocolytic drugs in countries studied
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Adjusted odds ratio† 
(95% CI)
Maternal age
Younger than 20 years 332 (9%) 437 (13·0%) 0·62 (0·50– 0·77) 0·70 (0·57–0·86)
20–35 years 3116 (80%) 2547 (75·5%) Ref Ref
Older than 35 years 443 (11%) 379 (11·2%) 0·96 (0·78–1·17) 0·95 (0·76–1·20)
Data missing 9 (<1%) 10 (<1%) ·· ··
Marital status
Married 378 (10%) 391 (12%) 0·82 (0·60–1·11) 1·25 (0·98–1·61)
Not married 3495 (90%) 2950 (88%) Ref Ref
Data missing 27 (1%) 32 (1%) ·· ··
Years of education
0 years 573 (15%) 603 (18%) 0·64 (0·41–0·99 0·84 (0·63–1·11)
1–6 years 576 (15%) 482 (14%) 0·8 (0·60–1·08) 0·83 (0·69–0·99)
7–9 years 723 (19%) 660 (20%) 0·74 (0·55–0·98) 0·87 (0·69–1·10)
10–12 years 1141 (29%) 875 (26%) 0·88 (0·69–1·12) 0·96 (0·80–1·15)
More than 12 years 584 (15%) 392 (12%) Ref Ref
Data missing 303 (8%) 361 (11%) ·· ··
Parity
0 1811 (46%) 1448 (43%) 1·06 (0·95–1·19) 1·20 (1·07–1·35)
1–2 children 1580 (41%) 1343 (40%) Ref Ref
More than 2 children 508 (13%) 577 (17%) 0·75 (0·61–0·91) 1·04 (0·85–1·27)
Data missing 1 (<1%) 5 (<1%) ·· ··
Mode of delivery
Vaginal delivery 2033 (52%) 2286 (68%) Ref Ref
Intrapartum caesarean section 874 (22%) 574 (17%) 1·71 (1·34–2·18) 1·51 (1·13–2·02)
No-labour caesarean section 984 (25%) 488 (15%) 2·27 (1·77–2·90) 2·13 (1·69–2·67)
Data missing 9 (<1%) 25 (1%) ·· ··
Maternal disorders
Chronic hypertension 114 (3%) 64 (2%) 1·56 (1·01–2·41) 1·14 (0·83–1·57)
Pre-eclampsia or eclampsia 714 (18%) 441 (13%) 1·49 (1·22–1·82) 1·14 (0·89–1·46)
Pyelonephritis 23 (1%) 9 (<1%) 2·22 (1·16–4·23) 1·90 (1·07–3·37)
Infl uenza-like illness 20 (1%) 7 (<1%) 2·25 (1·03–5·98) 1·56 (0·92–2·63)
Other systemic infections  or sepsis 85 (2%) 61 (2%) 1·21 (0·81–1·80) 1·28 (0·61–2·69)
HIV/AIDS or HIV wasting syndrome 21 (1%) 28 (1%) 0·65 (0·31–1·37) 1·59 (0·73–3·44)
Malaria or dengue fever 16 (<1%) 27 (1%) 0·51 (0·24–1·11) 0·90 (0·35–2·26)
Sex of infant 
Female 1796 (46·1%) 1592 (47%) 0·93 (0·85–1·03) 0·98 (0·90–1·06)
Male 2096 (53·7%) 1736 (52%) Ref Ref
Data missing 8 (0·2%) 45 (1%) ·· ··
Number of newborn babies
One (singleton pregnancy) 3574 (92% 3153 (94%) Ref Ref
Two (twin pregnancy) 296 (8%) 197 (6%) 1·33 (1·08–1·63) 3·59 (1·15–11·24)
Three or more (higher-order multiple pregnancy) 29 (1%) 6 (<1%) 4·26 (1·85–9·84) 1·28 (1·03–1·60)
Missing data 1 (<1%) 17 (1%) ·· ··
Location‡
Urban 3483 (89%) 2762 (82%) Ref Ref
Peri-urban 162 (4%) 358 (11%) 0·36 (0·17–0·77) 0·79 (0·58–1·07)
Rural 57 (2%) 96 (3%) 0·47 (0·29–0·77) 0·88 (0·77–1·01)
Data missing 198 (5%) 157 (5%) ·· ··
(Table 3 continues on next page)
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and tertiary (N=131 835, 43%) facilities, with the rest in 
primary (N=16 611, 6%) and other referral level (N=36 460 
12%) facilities; data were missing for 8·0% (N=24 196) of 
deliveries. The 7547 women who gave birth at 
26–34 weeks’ gestation accounted for 2·5% of all 
deliveries. Of these events, 4906 (65%) women had a 
spontaneous preterm birth, of which 4677 (95%) were 
spontaneous preterm births without a major 
contraindication to tocolysis. Table 1 shows data for 
antenatal corticosteroid use in the 17 705 women who 
delivered preterm; 766 (4%) had data missing for use of 
antenatal corticosteroids. Of the women who delivered at 
26–34 weeks’ gestation, 52% received antenatal 
corticosteroids (table 1). 
When stratifi ed by spontaneous preterm birth or 
provider-initiated preterm birth (ie, induced labour or a 
pre-labour caesarean section), antenatal corticosteroid use 
for women at 26–34 weeks’ gestation was similar (χ² =0·62). 
When analysed for countries, median antenatal cortico-
steroid coverage was 54% (range 16–91%, IQR 30–68%; 
table 2, appendix). Only two countries exceeded 80% use—
Jordan (91%) and occupied Palestinian territory (88%)—
however, the number of preterm babies in both countries 
was quite small. Although we did not know the vital status 
of the fetus at onset of labour, we did a sensitivity analysis 
by excluding the 1957 women who had stillbirth with signs 
of maceration (on the assumption that these fetuses were 
probably not alive at the start of labour). Use of antenatal 
corticosteroids increased from 52% (n=3900 of 7547) to 
56% (n=3836 of 6909) after we excluded these deliveries. 
Results from the multilevel logistic regression model with 
multiple imputation (table 3) showed that the adjusted 
odds of receipt of antenatal corticosteroids were 
signifi cantly raised in nulliparous women and in both 
intrapartum caesarean and pre-labour caesarean deliveries. 
Women with pyelonephritis had raised adjusted odds of 
antenatal corticosteroid receipt, as did those pregnant with 
twins and higher-order multiple pregnancies. The adjusted 
odds of antenatal corticosteroid use were lower in women 
younger than 20 years and women with 1–6 years of 
education. The same model without multiple imputation 
of missing values returned similar results (data not 
shown), with no change in signifi cance for covariates 
except for pyelonephritis (not signifi cant in model without 
multiple imputation; adjusted odds ratio 1·39, 95% CI 
0·79–2·43) and infl uenza (signifi cant in model without 
multiple imputation; 2·48, 1·56–3·93).
Among the 4677 women with uncomplicated, 
spontaneous preterm labour who were eligible for 
tocolytic treatment, almost half received no treatment 
and a quarter received non-drug treatments (table 4). 
The most frequently used drugs for tocolysis were 
β-agonists and calcium-channel blockers. Only 848 (18%) 










Adjusted odds ratio† 
(95% CI)
(Continued from previous page)
Level of facility‡
Primary 52 (1%) 82 (2%) 0·41 (0·22–0·78) 0·79 (0·52–1·22)
Secondary 663 (17%) 969 (29%) 0·45 (0·30–0·66) 0·93 (0·69–1·26)
Tertiary 2677 (69%) 1743 (52%) Ref Ref
Other referral level 309 (8%) 383 (11%) 0·53 (0·26–1·05) 1·03 (0·82–1·29)
Data missing 199 (5%) 196 (6%) ·· ··
Columns might not add to 100% because of rounding error. 274 women had information missing on receipt of antenatal corticosteroids and are not included. Ref=reference 
comparator group. *Calculation of crude odds ratios adjusted for clustering due to survey design only. †Multilevel logistic regression model adjusted for  maternal 
characteristics (age, marital status, education, parity, and mode of delivery), maternal disorders (chronic hypertension, pre-eclampsia or eclampsia, pyelonephritis, 
infl uenza-like illness, other infections or sepsis, HIV/AIDS, malaria, and dengue fever), infant characteristics (sex and number of fetuses), and facility characteristics (location 
and level of facility, provision of care free of charge at facility, and level of services available at facility), as well as clustering due to survey design. ‡As reported by head of 
obstetrics department or facility. 




Women receiving drugs for tocolysis 970 (21%)
Calcium-channel blocker only 271 (6%)
Oxytocin antagonist only 26 (1%)
β-agonists only 346 (7%)
NSAIDs or COX inhibitors only 48 (1%)
Magnesium sulphate only 85 (2%)
More than one drug given* 194 (4%)
No drug given; treated with bed rest and hydration only† 1276 (27%)
No treatment given for tocolysis 2248 (48%)
Data missing 183 (4%)
Data for 4677 deliveries. NSAIDs=non-steroidal anti-infl ammatory drugs. 
COX=cyclo-oxygenase.*Use of two or more tocolytic drugs including those listed. 
†No documented use of any of the named drugs or treatments. 
Table 4: Use of tocolytic drugs in women with uncomplicated, 
spontaneous preterm deliveries at 26–34 weeks’ gestation
See Online for appendix
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combination with antenatal corticosteroids (fi gure 2). 
Most women received neither a tocolytic drug nor 
antenatal corticosteroids, or antenatal corticosteroids 
without a tocolysis drug; and a few received tocolysis 
without concurrent antenatal corticosteroids. At the 
country level, rates of tocolytic drug use in combination 
with antenatal corticosteroids were generally low—
median rate was 19% (range 0–100; table 2, appendix).
Discussion
Our analysis showed that antenatal corticosteroids and 
tocolytic drugs were substantially underused in women 
in whom they would have been benefi cial. Use of 
antenatal corticosteroids at gestational ages at which 
benefi t is more controversial, or use of tocolytic drugs 
that are ineff ective or have higher rates of adverse 
outcomes, was common and exposed women and their 
babies to unnecessary risk. Nearly half of eligible women 
overall did not receive antenatal corticosteroids, and, in 
many countries, most eligible women did not receive 
antenatal corticosteroids. Lower-income countries such 
as Afghanistan, Democratic Republic of the Congo, 
Nepal, and Niger have particularly high rates of neonatal 
mortality15 and low use of antenatal corticosteroids. 
Antenatal corticosteroid use in the two high-income 
countries that we assessed (Japan 56% and Qatar 31%) 
was surprisingly low; however, this fi nding must be 
interpreted cautiously because the number of women 
(52 and 29, respectively) was quite small. Although there 
are few reports of antenatal corticosteroid use in 
low-income and middle-income countries (panel), other 
investigators have noted similarly wide variations—eg, 
4–71% of women received corticosteroids in several Latin 
American countries16–20 and 9–73% of women in 
four southeast Asian countries.21 Of perhaps greater 
concern is that use of antenatal corticosteroids was low 
even in preterm births after induction or pre-labour 
caesarean section; deliveries in which the timing of 
delivery and need for antenatal corticosteroids could be 
reasonably anticipated. Although we were unable to 
explore specifi c reasons to explain this fi nding, it suggests 
that barriers to poor use of antenatal corticosteroids 
probably extend beyond poor identifi  cation of women at 
risk of preterm delivery. Almost a quarter of women who 
delivered at 35–36 weeks’ gestation received antenatal 
corticosteroids despite the fact that perinatal morbidity 
and mortality benefi t at these gestational age intervals is 
somewhat controversial.2 Uncertainty about gestational 
age is common in low-income and middle-income 
countries because antenatal care participation and 
ultrasound availability can be poor—this uncertainty 
might have contributed to use of antenatal corticosteroids 
in gestational ages outside of the 26–34 weeks’ gestation 
range. More appropriate prescribing practices could 
improve outcomes for the 45% of women at 26–34 weeks’ 
gestation who did not receive antenatal corticosteroids.
The use of tocolytics was generally poor, but it is of 
great concern that more than a third of eligible women 
received ineff ective treatments for preterm labour. No 
evidence exists to support the use of bed rest22 and 
hydration (if not dehydrated)23 to prevent preterm delivery, 
and magnesium sulphate is not eff ective to delay birth or 
prevent preterm birth.24 Haas and colleagues3 did a 
systematic review and network meta-analysis for drug 
treatment options to prevent preterm delivery and 
reported that prostaglandin inhibitors and 
calcium-channel blockers have the highest probability of 
improving neonatal outcomes by delaying delivery and 
have the lowest maternal side-eff ects. Prostaglandin 
inhibitor use is complicated by the risk of oligo-
hydramnios and premature closure of the fetal ductus 
arteriosus.25 Nifedipine is comparatively cheaper,26 is 
simple to administer, and is the only drug for tocolysis in 
the WHO Essential Medicines List.27 β-agonists have 
similar eff ectiveness to calcium-channel blockers,11 but 
they have higher rates of maternal adverse eff ects (such 
as chest pain, breathing diffi  culties, heart irregularities, 
headaches, and shaking). In our analysis, β-agonists were 
the most commonly used eff ective tocolytic drug, despite 
the known maternal side-eff ects, and only 6% of eligible 
women received calcium-channel blockers. This pattern 
might be due to historical reasons; however, it shows that 
changes in tocolytic prescribing practices could improve 
both maternal and neonatal outcomes. Ideally, women in 
spontaneous preterm labour between 26 and 24 weeks of 
gestation who receive tocolytics should recieve antenatal 
corticosteroids in combination, yet only 15% of eligible 
women received both treatments and 42% received 
neither. As far as we know, our data are the fi rst 
international comparison of tocolytic drug use with 
antenatal corticosteroids in preterm birth across 
lower-income countries. Further research on the 
determinants of tocolytic prescription would help to 
identify interventions to improve compliance with best 
practices in preterm labour management.
A 2013 survey by Aleman and colleagues28 identifi ed 
several barriers to improved uptake of antenatal 
Figure 2: Use of tocolytic drugs, with and without antenatal corticosteroids, in 
uncomplicated spontaneous preterm births (26–34 weeks’ gestation; n=4677)
Tocolytic drugs for preterm labour include calcium-channel blockers, oxytocin 
antagonists, β-agonists, non-steroidal anti-infl ammatory drugs and 
cyclooxygenase inhibitors, and magnesium sulphate. The no tocolytic drug 
group indicates women treated with bed rest, hydration, or no treatment for 
preterm labour.
186 (4%) women for
whom data missing 848 (18%) women
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corticosteroids in four Latin American countries, 
including corticosteroids not being available at hospitals 
and primary health centres, fear or doubt among health 
providers about side-eff ects, misinformation about 
correct use, and insuffi  cient personnel. They also reported 
economic barriers to access, and fear and misinformation 
among women about antenatal corticosteroids.28 
Although we were unable to identify specifi c barriers for 
the use of antenatal corticosteroids and tocolytic drugs, 
younger women and women with little education were 
less likely to receive corticosteroids than were others, 
suggesting social inequalities might be at play.
Our fi ndings have substantial implications for both 
clinicians and health policy makers. If recognition of 
preterm labour is to be followed by early antenatal 
corticosteroids (with or without tocolytic drugs) then drugs 
should be readily available at the time and place of 
presentation. We therefore recommend inclusion of 
dexamethasone or betamethasone or both on national 
essential medicines lists to improve outcomes for preterm 
babies. This action would improve access in all health 
facilities, particularly in lower-level facilities, which are 
often the point of fi rst contact for women in preterm labour. 
Additionally, despecialising prescription of antenatal 
corticosteroids could allow some health professionals (such 
as emergency doctors and midwives) to give these drugs 
could reduce delays in access to this life-saving intervention. 
2012 WHO guidance for task shifting29 recommends that 
the use of midwives to give corticosteroids in preterm 
labour should be researched rigorously.
In facilities where antenatal corticosteroids and 
tocolytic drug are available but underused or misused, 
implementation research, including a deeper under-
standing of barriers to their use, is needed. Clinical 
guidelines and education for all health-care workers to 
recognise and manage preterm labour can reduce barriers 
to increased use. Interventions to increase demand could 
also change practice. For example, community mob-
ilisation and provision of antenatal corticosteroids free of 
charge to all women at risk of preterm labour would not 
only increase demand, but would also address the 
socioeconomic inequities in antenatal corticosteroid use 
and improve coverage in higher-risk subpopulations (such 
as adolescents and poorly educated mothers).
Some limitations could have aff ected the results of our 
analysis. WHOMCS was mainly a study of maternal and 
perinatal morbidity and mortality, of which preterm birth 
is an important component, but was not the survey’s 
main aim. The number of countries participating in the 
multicountry survey was limited by fi nancial constraints; 
hence, Europe was not sampled. Although robust, the 
multistage facility sampling design could potentially 
introduce bias, because women from countries with 
smaller populations are oversampled compared with 
women from countries with larger populations. Within 
the same country, when smaller, lower-level facilities are 
randomly sampled, complicated deliveries might be 
under-represented. Convers ely, in countries where 
maternity care is centralised in a few, large facilities 
(particularly in the capital city) or where such facilities 
were randomly sampled, complicated deliveries are 
probably over-represented. These data are probably not 
representative of smaller facilities and communities not 
included in the sampling frame; however, we believe it is 
reasonable to assume that antenatal corticosteroid and 
tocolytic drug availability is high in large facilities, and 
that higher-level facilities and coverage rates are probably 
poorer in lower-level facilities. In some countries, the 
number of deliveries in lower-level facilities is 
proportionally greater, thus coverage might still be poor 
even when the national rate of facility delivery is high. 
Data for WHOMCS were abstracted from hospital 
records; in many facilities, these records are suboptimum 
and use of interventions might not have been 
documented correctly (particularly those occurring 
before facility admission). This bias was minimised as 
much as possible because data collectors consulted with 
medical staff  about missing information; however, some 
treatment might be undocumented or could have 
occurred before arrival at the facility, leading to a possible 
underestimation of coverage. Conversely, failure to 
recognise preterm births due to poor estimation of 
gestational age might lead to an overestimate of drug 
use. Under-recognition of prematurity also probably 
contributed to the recorded preterm birth rate (5·8%) 
being lower than was expected based on recent estimates.1 
Fetal status on arrival for delivery, as well as the type, 
timing, dose, and frequency of antenatal corticosteroids 
and tocolytic drugs, was not included in WHOMCS, and 
we were unable to account for all contraindications to 
these drugs (such as drug allergies, maternal cardiac 
diseases, and advanced cervical dilatation). A small 
proportion of antenatal corticosteroid use at 35–36 weeks’ 
Panel: Research in context
Systematic review
In women at 26–34 weeks’ gestation at risk of preterm birth, the effi  cacy of antenatal 
corticosteroids to accelerate fetal lung maturation is unquestioned; contributors to a 
2006 Cochrane review2 explored the subject extensively. Similarly, the effi  cacy and adverse 
eff ects of individual tocolytic drugs (such as betamimetics,10 calcium-channel blockers,11 
oxytocin receptor antagonists,12 and magnesium sulphate24) have been the subject of 
Cochrane reviews.
Interpretation 
Despite the wealth of trial evidence about the effi  cacy and indications for antenatal 
corticosteroids and tocolytic drugs in preterm birth, remarkably little data are available for 
clinical patterns of their use, particularly in low-income and middle-income countries where 
most of the global burden of preterm-associated neonatal mortality occurs. Our fi ndings 
provide the fi rst internationally comparable, comprehensive study of prevalence of use for 
antenatal corticosteroids. We suggest that a substantial amount of preterm-birth-associated 
newborn morbidity and mortality could be avoided through improvements in the delivery of 
these known interventions. Intensive eff orts to scale up use of antenatal corticosteroids in 
facility settings are needed.
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gestation might be attributable to women who were 
treated earlier than 35 weeks’ gestation but who delivered 
after 35 weeks’ during the same admission. Although 
missing data might have led to a bias in our fi ndings, 
missing rates were generally low (≤5%) and results from 
modelling, both with and without multiple imputation, 
were similar, increasing our confi dence that missing 
values had negligible eff ect.
Despite the evidence for eff ectiveness of antenatal 
corticosteroids and tocolytic drugs in preterm deliveries, 
their use was highly variable and often poor. A substantial 
proportion of antenatal corticosteroid use was at extremes 
of gestational age when benefi t is controversial, whereas 
a signifi cant proportion of mothers of infants at 
26–34 weeks’ gestation did not receive this life-saving 
intervention. The use of ineff ective, less eff ective, or 
potentially harmful treatments for tocolysis was also 
widespread. Implementation research and contextualised 
health policies are needed to improve drug availability 
and compliance with best obstetric practices.
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